Study reveals how #PancreaticCancer #tumors evade #immunity using a sugar disguise, and how a new #AntibodyTherapy restores immunity in mice.
#ImmuneEvasion #TherapyResistance
        
            #ImmuneEvasion #TherapyResistance
New antibody therapy reawakens immune system to fight pancreatic cancer – BioNews Central
            Study reveals how pancreatic cancer tumors evade immunity using a sugar disguise, and how a new antibody therapy restores immunity in mice. ...
          
            
            sbee.link
          
        
          
            November 3, 2025 at 5:30 PM
            
              
              Everybody can reply
            
          
        The Antibody Drug Discovery Market drives innovation in targeted therapeutics. 🧫💉 www.marketresearchfuture.com/reports/anti... #Biopharma #DrugDiscovery #AntibodyTherapy
        
            Antibody Drug Discovery Market Size, Growth Statistics 2035
            Antibody Drug Discovery Market Industry is expected to grow from 48.97(USD Billion) in 2024 to 89.6(USD Billion) by 2035. The Antibody Drug Discovery Market CAGR (growth rate) is expected to be around...
          
            
            www.marketresearchfuture.com
          
        
          
            October 7, 2025 at 7:27 AM
            
              
              Everybody can reply
            
          
        🧪 Mini antibodies, massive potential! 🧬 Transforming immunotherapy & diagnostics with next-gen antibody platforms.
#Biologics #AntibodyTherapy #PharmaInnovation
www.marketresearchfuture.com/reports/sing...
        
          #Biologics #AntibodyTherapy #PharmaInnovation
www.marketresearchfuture.com/reports/sing...
Single Domain Antibody Platform Market Size, Trends 2032 | MRFR
            Single Domain Antibody Platform Market 2025, Industry to reach USD 4.2 Billion, at 8.24% CAGR by growing size, share, top company analysis, segments research, trends and forecast report 2032.
          
            
            www.marketresearchfuture.com
          
        
          
            September 15, 2025 at 7:30 AM
            
              
              Everybody can reply
            
          
        
          
          
          1 likes
          
        
        
      
    US-owned private hospital operator HCA Healthcare has introduced bispecific antibody therapy for patients with extensive-stage small-cell lung cancer. 
healthcaretoday.com/article/hca-...
#healthcare #lungcancer #antibodytherapy #patientsafety
        
            healthcaretoday.com/article/hca-...
#healthcare #lungcancer #antibodytherapy #patientsafety
HCA Healthcare launches bispecific antibody therapy
            The treatment for stage small cell lung cancer is not available on the NHS, and this is the first time a lung cancer patient has been treated with this therapy at a HCA Healthcare UK hospital.
          
            
            healthcaretoday.com
          
        
          
            August 27, 2025 at 8:58 AM
            
              
              Everybody can reply
            
          
        GPCR Antagonism via Antibody-Mediated Rewiring of Receptor Trafficking and Degradation
Adachi, A., Adelman, K. et al.
Paper
Details
#GPCRMechanisms #AntibodyTherapy #ReceptorTargeting
          Adachi, A., Adelman, K. et al.
Paper
Details
#GPCRMechanisms #AntibodyTherapy #ReceptorTargeting
            August 12, 2025 at 4:01 PM
            
              
              Everybody can reply
            
          
        #4TEEN4 #4TEEN4Pharmaceuticals #antibodytherapy #cardiogenicshock #phase1b/2astudy #procizumab #monoclonalantibody #PROCARD1trial  #circulatingdipeptidylpeptidase3 #cDPP3 #cardiacdepressionfactor #shock #cDPP3inhibitor #angiotensinII #PROCARD1study 
pharmatimes.com/news/4teen4-...
        
            pharmatimes.com/news/4teen4-...
4TEEN4 begins trial of antibody therapy for cardiogenic shock - PharmaTimes
            First patient dosed in phase 1b/2a study of procizumab
          
            
            pharmatimes.com
          
        
          
            August 1, 2025 at 10:32 AM
            
              
              Everybody can reply
            
          
        Scientists Unveil New Antibody That Supercharges Immune Attack on Tumors #Science #HealthandMedicine #Oncology #Immunotherapy #CancerResearch #AntibodyTherapy
        
            Scientists Unveil New Antibody That Supercharges Immune Attack on Tumors
            The antibody PLT012 targets the fat transporter CD36 to restore immune responses in tumors, offering a new and promising approach to treating immunotherapy-resistant cancers. A new study from Ludwig Cancer...
          
            
            purescience.news
          
        
          
            May 23, 2025 at 5:45 AM
            
              
              Everybody can reply
            
          
        
          1 reposts
          
          1 likes
          
        
        
      
    The Antibody From a Survivor That Outsmarts Ebola – With a Tiny Dose #Science #HealthandMedicine #InfectiousDiseases #EbolaResearch #AntibodyTherapy #PublicHealth
        
            The Antibody From a Survivor That Outsmarts Ebola – With a Tiny Dose
            A team of scientists has uncovered the remarkable potential of a human antibody, mAb 3A6, in fighting Ebola virus infections. Sourced from a survivor of the devastating 2014–2016 outbreak, this antibody...
          
            
            purescience.news
          
        
          
            April 25, 2025 at 6:01 PM
            
              
              Everybody can reply
            
          
        This approach could pave the way for next-generation immunotherapies, expanding the potential of antibody-based treatments! 🧬💡
www.science.org/doi/10.1126/...
#Immunotherapy #TCRm #AntibodyTherapy #CAR-T #CancerResearch #Biotech #PrecisionMedicine
        
            www.science.org/doi/10.1126/...
#Immunotherapy #TCRm #AntibodyTherapy #CAR-T #CancerResearch #Biotech #PrecisionMedicine
CAR T cells based on fully human T cell receptor–mimetic antibodies exhibit potent antitumor activity in vivo
            Development of fully human T cell receptor–mimetic antibodies enabled the generation of CAR T therapies against intracellular tumor-specific antigens.
          
            
            www.science.org
          
        
          
            March 28, 2025 at 4:32 AM
            
              
              Everybody can reply
            
          
        🥳 Our 2nd most downloaded article in 2024: 
Cancer therapy with antibodies by Paul, Gabelli, Ho, van Elsas et al.
https://bit.ly/3EjrG...
#drugdevelopment #cancertherapy #antibodytherapy
@natureportfolio.bsky.social #NRCtop10of2024
        
            Cancer therapy with antibodies by Paul, Gabelli, Ho, van Elsas et al.
https://bit.ly/3EjrG...
#drugdevelopment #cancertherapy #antibodytherapy
@natureportfolio.bsky.social #NRCtop10of2024
Cancer therapy with antibodies - Nature Reviews Cancer
            In this Review, Paul et al. provide an overview of therapeutic antibodies as an important modality in cancer therapy today. They summarize the different approaches used by antibodies to target cancer cells including those of immune checkpoint inhibitors, bispecific antibodies...
          
            
            bit.ly
          
        
          
            February 13, 2025 at 2:16 PM
            
              
              Everybody can reply
            
          
        
          2 reposts
          1 quotes
          9 likes
          
        
        
      
    #NICEnews #NICErecommended #Neuraxpharm #ublituximab #BRIUMVI #MABS #MS #multiplesclerosis #MStreatment  #multiplesclerosistreatment #patientoutcomes #antibodytherapy #NeuraxpharmGroup  #relapsingremittingmultiplesclerosis #RRMS #MSpatients  #TGTherapeutics 
pharmatimes.com/news/nice-en...
        
            pharmatimes.com/news/nice-en...
NICE endorses Neuraxpharm's ublituximab for treating MS - PharmaTimes
            New antibody therapy shows promise in managing condition
          
            
            pharmatimes.com
          
        
          
            December 5, 2024 at 2:23 PM
            
              
              Everybody can reply
            
          
        
          
          
          1 likes
          
        
        
      
    #BiotechInnovation
#ImmuneResponse
#LymphomaTreatment
#ClinicalTrials
#CellEngineering
#CytokineTherapy
#NextGenMedicine
#PersonalizedMedicine
#RegenerativeMedicine
#CellAndGeneTherapy
#TumorMicroenvironment
#CancerCare
#TCellActivation
#AntibodyTherapy
#ResearchForACure
          #ImmuneResponse
#LymphomaTreatment
#ClinicalTrials
#CellEngineering
#CytokineTherapy
#NextGenMedicine
#PersonalizedMedicine
#RegenerativeMedicine
#CellAndGeneTherapy
#TumorMicroenvironment
#CancerCare
#TCellActivation
#AntibodyTherapy
#ResearchForACure
            November 17, 2024 at 12:38 AM
            
              
              Everybody can reply
            
          
        Fibrin fuels thromboinflammation and brain damage in COVID-19 🔬🧠💉 www.news-medical.net/news/2024082... #COVID19 #Fibrin #Thromboinflammation #Neuropathology #AntibodyTherapy #LongCOVID #ImmuneResponse #Brain #Health #ViralResearch @natureportfolio.bsky.social
        
            Fibrin fuels thromboinflammation and brain damage in COVID-19
            Researchers reveal fibrin's critical role in COVID-19 by driving thromboinflammation and neuropathology, and highlight a potential antibody therapy to mitigate these effects.
          
            
            www.news-medical.net
          
        
          
            August 30, 2024 at 2:49 AM
            
              
              Everybody can reply
            
          
        
          1 reposts
          
          3 likes
          
        
        
      
    Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants 🦠🧬💉 www.news-medical.net/news/2024050... #COVID19Research #Bispecific #Antibodies #Omicron #Variants #Vaccine #AntibodyTherapy #Pandemic #ViralNeutralization #SARSCoV2 @biorxivpreprint.bsky.social
        
            Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants
            Researchers developed bispecific antibodies targeting both the N-terminal and receptor binding domains of SARS-CoV-2, demonstrating significant neutralization across various Omicron variants, suggesti...
          
            
            www.news-medical.net
          
        
          
            May 9, 2024 at 4:40 AM
            
              
              Everybody can reply